« Return to News | CROs/Service Providers

Parexel Profits Down in Q2, Revenues Up

Tuesday, January 27, 2009 08:00 AM

Parexel’s second quarter financial results, released late Monday, reflect the ill effects of negative foreign exchange rates and a recently terminated contract.

The Waltham, Mass.-based contract research organization (CRO) reported an increase in service revenues for the second quarter of 2009 compared with the prior year, but year-over-year profits were cut by more than half from $11.5 million in the second quarter 2007 to $5.2 million for the quarter ended December 31, 2008.

Service revenues increased 15.6% to $275.8 million for the second quarter of fiscal year 2009, up from $238.7 in the prior year period.

"With regard to our outlook for the current calendar year, I remain cautiously optimistic. While we may experience a slow-down in the small biopharma client segment due to the current condition of the financial markets, I believe that this impact may be offset by an increase in outsourcing levels from larger clients,” said Parexel chairman and CEO Josef von Rickenbach in a company release.

Earlier this month, funding difficulties caused the sponsor of a large clinical trial to pull out of a contract with Parexel, and the sponsor subsequently filed for bankruptcy protection. Parexel terminated its contract with the client and recorded $15 million in pre-tax reserves in the second quarter for anticipated wind-down costs and bad debt expense related to impaired accounts receivable.

Parexel's share prices were up 26% to $9.30 in morning trading.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.